Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE

Herein we investigated how rituximab-induced B cell depletion affected leukocyte subpopulations and antibody titers in SLE patients. We focused our analysis on time points related to absence and return of B cells after depletion. A correlation was found between the baseline frequency and time to rep...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 122(2007), 1 vom: 01. Jan., Seite 62-74
1. Verfasser: Vallerskog, Therese (VerfasserIn)
Weitere Verfasser: Gunnarsson, Iva, Widhe, Mona, Risselada, Anke, Klareskog, Lars, van Vollenhoven, Ronald, Malmström, Vivianne, Trollmo, Christina
Format: Aufsatz
Sprache:English
Veröffentlicht: 2007
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Autoantibodies Immunoglobulins Immunologic Factors Rituximab 4F4X42SYQ6